NFKB1 and non-Hodgkin lymphoma: The finding that more than 90% of cases of Waldenström Macroglobulinemia (WM), a non-Hodgkin lymphoma with plasmacytic features, have MYD88L265P mutations [97,98] implicates a crucial role of the aberrant activity of the canonical NF-κB pathway in this disease.